A Steroid-Sparing Breakthrough(Obexelimab) for IgG4-Related Disease: NEJM | June 2026

Introduction:

IgG4-related disease (IgG4-RD) is a chronic fibroinflammatory disorder that can affect virtually any organ. Although glucocorticoids remain the mainstay of treatment, relapse is common after tapering, and long-term steroid toxicity remains a major concern. The INDIGO trial evaluated obexelimab, a novel B-cell modulator, as a steroid-sparing therapy.

Why was this study needed?

• Relapse is common after glucocorticoid withdrawal in IgG4-RD.
• Long-term corticosteroid therapy is associated with substantial toxicity.
• Effective steroid-sparing therapies are limited.
• Conventional B-cell depletion has safety and relapse concerns.
• Novel targeted therapies are needed to maintain durable remission.

Results:

• Obexelimab significantly reduced disease flares, prolonging flare-free survival compared with placebo over 52 weeks.
• Patients receiving obexelimab achieved higher complete remission rates while requiring substantially less rescue glucocorticoid therapy.
• Obexelimab was well tolerated, with fewer serious adverse events than placebo despite mild increases in arthralgia, hypersensitivity, and diarrhea.

Clinical Impact:

The INDIGO trial establishes obexelimab as the first phase III biologic to demonstrate robust steroid-sparing efficacy in IgG4-related disease. Unlike conventional B-cell-depleting therapies, obexelimab modulates B-cell activity without depleting B cells, offering a novel therapeutic approach with the potential to reduce long-term corticosteroid exposure.

Bottom Line:

Obexelimab represents a major therapeutic advance for IgG4-related disease. It significantly reduces disease flares, increases sustained remission, and minimizes glucocorticoid exposure, making it a promising new targeted treatment for this chronic multisystem disorder.